LLY
Eli Lilly and Company
LLY has the edge over STLN overall, supported by lower modeled downside and stronger valuation.
STLN
Starling Oncology, Inc.
STLN's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
STLN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Stable | |
| Unavailable |
STLN's revenue is currently healthy, and its profitability and cash flow are stable. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
STLN PE Valuation
STLN has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
STLN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect STLN's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over STLN on earnings quality, reporting a profit while its opponent remains loss making.
STLN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.27 | +$0.37 |
| Q2 2026 | -$0.28 | +$0.40 |
| Q1 2026 | -$0.35 | +$0.35 |
| Q4 2025 | -$0.54 | +$0.17 |
| Q3 2025 | -$0.64 | +$0.14 |
| Q2 2025 | -$0.68 | +$0.11 |
| Q1 2025 | -$0.70 | +$0.11 |
| Q4 2024 | -$0.71 | +$0.21 |
STLN is still losing money, but far less than before: $0.27 per share over the past year, against $0.92 at its worst in late 2023.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over STLN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over STLN on profitability, with a higher operating margin.
STLN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $169.8M | +24% |
| Q2 2026 | $161.3M | +35% |
| Q1 2026 | $147.4M | +41% |
| Q4 2025 | $142M | +42% |
| Q3 2025 | $136.6M | +37% |
| Q2 2025 | $119.8M | +22% |
| Q1 2025 | $104.4M | +10% |
| Q4 2024 | $100.3M | +17% |
STLN's revenue has grown year over year every quarter since early 2023: $170M last quarter, up 24% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1.8% | +4.1 points |
| Q2 2026 | -2.9% | +6.5 points |
| Q1 2026 | -4.4% | +5.1 points |
| Q4 2025 | -4.9% | +7 points |
| Q3 2025 | -5.9% | +8 points |
| Q2 2025 | -9.4% | +7.2 points |
| Q1 2025 | -9.5% | +9.5 points |
| Q4 2024 | -12% | +5.9 points |
STLN's operating margin was −1.8% last quarter, up 4.1 points from the same quarter a year ago, near the top of its range since 2022.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
STLN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.9M | +$22.1M |
| Q2 2026 | $11M | +$22.4M |
| Q1 2026 | -$3.3M | +$2.1M |
| Q4 2025 | $2.2M | -3.2% |
| Q3 2025 | -$13.2M | -1184% |
| Q2 2025 | -$11.4M | +$6.1M |
| Q1 2025 | -$5.3M | +$11.2M |
| Q4 2024 | $2.2M | +$7M |
STLN's free cash flow has turned positive after six years mostly in the red: $19M over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over STLN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
STLN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.6% | +1.7M shares |
| 1 year | +7.4% | +7.3M shares |
| 3 years | +43% | +31.3M shares |
| 5 years | +1721% | +99M shares |
STLN has 105M diluted shares, up 7.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q4 2023 | — |
| Q3 2023 | $125,000 |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $9M |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
STLN Net Leverage
STLN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
STLN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.7 | Neutral |
| Stochastic | 31.0 | Neutral |
STLN's weekly RSI is 37 (neutral) and its Stochastic is 31 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
STLN PE vs Healthcare Sector
STLN has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over STLN on trend strength, trading above more of its moving averages.
STLN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.83 | 36% below |
| 20 week MA | $5.88 | 36% below |
| 50 week MA | $4.53 | 17% below |
| 100 week MA | $3.49 | 7.4% above |
| 200 week MA | $2.25 | 67% above |
STLN has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 67% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over STLN on returns for 2026, with the stronger performance.
STLN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.84 | $10.8 | +9.8% |
| 2021 | $10.8 | $10.4 | -3.3% |
| 2022 | $10.4 | $1.60 | -85% |
| 2023 | $1.60 | $2.04 | +27% |
| 2024 | $2.04 | $0.32 | -84% |
| 2025 | $0.32 | $3.64 | +1038% |
| 2026 YTD | $3.64 | $3.75 | +3% |
STLN's yearly returns have swung widely, from +1038% in 2025 to −85% in 2022. It's up 3% so far in 2026.